BioXcel Therapeutics Inc [BTAI] stock prices are up 85.40% to $2.54 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BTAI shares have gain 49.41% over the last week, with a monthly amount glided 31.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioXcel Therapeutics Inc [NASDAQ: BTAI] stock has seen the most recent analyst activity on February 21, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $4 from $9. Previously, Mizuho downgraded its rating to Neutral on August 15, 2023, and dropped its price target to $4. On July 17, 2023, downgrade downgraded it’s rating to Neutral. Jefferies downgraded its rating to a Hold and increased its price target to $22 on March 10, 2023. Goldman upgraded its rating to a Neutral but $16 remained the price target by the analyst firm on December 01, 2022. Mizuho started tracking with a Buy rating for this stock on July 07, 2022, and assigned it a price target of $19. In a note dated April 06, 2022, BofA Securities reiterated an Buy rating on this stock but restated the target price of $80.
The stock price of BioXcel Therapeutics Inc [BTAI] has been fluctuating between $1.17 and $16.72 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. BioXcel Therapeutics Inc [NASDAQ: BTAI] shares were valued at $2.54 at the most recent close of the market. An investor can expect a potential return of 372.44% based on the average BTAI price forecast.
Analyzing the BTAI fundamentals
The BioXcel Therapeutics Inc [NASDAQ:BTAI] reported sales of 1.85M for trailing twelve months, representing a drop of -71.13%. Gross Profit Margin for this corporation currently stands at -0.11% with Operating Profit Margin at -29.7%, Pretax Profit Margin comes in at -21.63%, and Net Profit Margin reading is -21.63%. To continue investigating profitability, this company’s Return on Assets is posted at -1.04, Equity is 0.47 and Total Capital is -4.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that BioXcel Therapeutics Inc [NASDAQ:BTAI]’s Current Ratio is 1.48. As well, the Quick Ratio is 1.45, while the Cash Ratio is 1.21. Considering the valuation of this stock, the price to sales ratio is 8.31.
Transactions by insiders
Recent insider trading involved O’Neill Vincent, that happened on Dec 16 ’24 when 165.0 shares were sold. CEO and President, Mehta Vimal completed a deal on Dec 16 ’24 to sell 3117.0 shares. Meanwhile, Chief Financial Officer Steinhart Richard I sold 577.0 shares on Dec 16 ’24.
